Treatment of Obstructive Sleep Apnoea for Cognitive Decline in Mild Cognitive Impairment

Not Applicable

• Conditions: Obstructive Sleep Apnea; Mild Cognitive Impairment (MCI); Respiratory - Sleep apnoea; Neurological - Dementias

• Registration Number: ACTRN12614000442606
• Lead Sponsor: niversity of Sydney

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2014-04-29
• Study Completion: 2019-09-04
• Last Update Posted: 31 January 2022

Recruitment & Eligibility

• Status: Stopped early
• Sex: All
• Target Recruitment: 29

Inclusion Criteria

To be eligible, participants must:
1. Have the presence of at least moderate OSA as defined by an AHI of greater than or equal to 15 as defined by PSG using the criteria of 4% O2 desaturation for events.
2. Have a diagnosis of single- or multi-domain Mild Cognitive Impairment (MCI) as determined by neuropsychological examination using a standardized research neuropsychological battery.
3. Have stability of at least four weeks on permitted medications (i.e. medications known not to affect sleep architecture or circadian rhythms).
4. Be fluent in English
5. Be willing and able to complete baseline, three month and six month outcome measures
6. Be willing to send in CPAP Smartcard for adherence testing

Exclusion Criteria

Participants will be excluded if they have:
1. Suspected dementia or a score of <24 on the Mini-Mental State Examination
2. A history of cerebrovascular events (e.g., stroke, TIA)
3. Planned shift-work or transmeridian travel within timeline of study (six months from baseline)
4. A diagnosis of neurological disorders (e.g. Parkinson's Disease, Epilepsy, Multiple Sclerosis)
5. Head trauma with associated loss of consciousness > 30mins or head injury with persisting cognitive deficits
6. Psychiatric disorders including current major depression; Bipolar Disorder (I and II); schizophrenia
7. Been taking tricyclic antidepressants (TCAs), Monoamine Oxidase Inhibitors (MAOIs), benzodiazepines, sedative hypnotics, antipsychotics, mood stabilisers, modafinil or stimulants, cholinesterase inhibitors or medications known to affect sleep architecture and/or circadian rhythms (e.g. Lithium)
8. Current substance abuse or dependence (alcohol and/or other illicit substances)
9. Any significant systematic illness or medical condition that may hinder compliance with treatment protocol
10. Any current known conditions that may increase short-term risk from untreated OSA
11. Other known clinically significant sleep disorders (e.g. narcolepsy)
12. Been currently receiving CPAP or bi-level pressure for OSA
13. Requirements of oxygen or bi-level pressure during the CPAP titration PSG (PSG used to determine specifications for CPAP administration)

Study & Design

• Study Type: Interventional
• Study Design: Not specified